Calamos Advisors
BPMC

Calamos Advisors’s Blueprint Medicines BPMC Stock Holding History

Calamos Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,721
Closed -$329K – 930
2025
Q1 		$329K Buy
+3,721
New +$363K ﹤0.01% 759
2024
Q3 		– Sell
-7,022
Closed -$757K – 947
2024
Q2 		$757K Sell
7,022
-1,134
-14% -$114K ﹤0.01% 678
2024
Q1 		$774K Buy
+8,156
New +$699K ﹤0.01% 673

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Calamos Advisors's BPMC Position: Q2 2025 in Review

Calamos Advisors sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3,721 shares — an estimated $329K sold.

Calamos Advisors first reported a position in BPMC in Q1 2024 and held it in 3 quarters. The position peaked at $774K in Q1 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Calamos Advisors reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Calamos Advisors sold 3,721 Blueprint Medicines shares in Q2 2025, an estimated $329K.
  • Calamos Advisors first reported a position in Blueprint Medicines in Q1 2024 and held it in 3 quarters.
  • Calamos Advisors's Blueprint Medicines position peaked at $774K in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Calamos Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.